Dimensional Fund Advisors LP grew its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 58.0% in the second quarter, according to its most recent filing with the SEC. The fund owned 726,760 shares of the biotechnology company’s stock after acquiring an additional 266,790 shares during the quarter. Dimensional Fund Advisors LP owned about 1.67% of United Therapeutics Corporation worth $94,286,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Eagle Global Advisors LLC bought a new position in shares of United Therapeutics Corporation during the 2nd quarter valued at approximately $206,000. Clarity Capital KCPS Ltd. bought a new position in shares of United Therapeutics Corporation during the 1st quarter valued at approximately $230,000. TLP Group LLC bought a new position in shares of United Therapeutics Corporation during the 2nd quarter valued at approximately $246,000. HPM Partners LLC boosted its position in shares of United Therapeutics Corporation by 0.8% during the 2nd quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock valued at $257,000 after acquiring an additional 15 shares during the last quarter. Finally, Fort L.P. boosted its position in shares of United Therapeutics Corporation by 5.2% during the 2nd quarter. Fort L.P. now owns 2,014 shares of the biotechnology company’s stock valued at $261,000 after acquiring an additional 99 shares during the last quarter.

A number of research analysts have recently commented on the company. BidaskClub downgraded United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of United Therapeutics Corporation in a research report on Friday, September 8th. ValuEngine downgraded United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Zacks Investment Research downgraded United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Finally, Jefferies Group LLC reiterated a “sell” rating and set a $105.00 target price on shares of United Therapeutics Corporation in a research report on Friday, July 14th. Six equities research analysts have rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $132.09.

In other United Therapeutics Corporation news, CEO Martine A. Rothblatt sold 1,236 shares of United Therapeutics Corporation stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $131.62, for a total value of $162,682.32. Following the sale, the chief executive officer now owns 1,376 shares in the company, valued at $181,109.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christopher Causey sold 580 shares of United Therapeutics Corporation stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $134.48, for a total value of $77,998.40. Following the completion of the sale, the director now owns 3,295 shares in the company, valued at approximately $443,111.60. The disclosure for this sale can be found here. Insiders have sold 16,462 shares of company stock worth $2,097,116 in the last three months. 7.80% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Dimensional Fund Advisors LP Boosts Stake in United Therapeutics Corporation (UTHR)” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.watchlistnews.com/dimensional-fund-advisors-lp-boosts-stake-in-united-therapeutics-corporation-uthr/1609885.html.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) opened at 122.21 on Thursday. The company’s 50-day moving average price is $124.90 and its 200 day moving average price is $127.07. The stock has a market cap of $5.31 billion, a price-to-earnings ratio of 14.17 and a beta of 1.49. United Therapeutics Corporation has a 12-month low of $110.90 and a 12-month high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.61 by ($4.86). The company had revenue of $444.60 million for the quarter, compared to analyst estimates of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period last year, the firm posted $4.42 EPS. On average, equities analysts predict that United Therapeutics Corporation will post $10.60 earnings per share for the current year.

United Therapeutics Corporation Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.